|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, February 05, 2016 ) Retinoic acid-related orphan nuclear receptor gamma (RORgamma) is a hot, but "difficult-to-drug" target. More than 30 companies are active in drug discovery and development. Technology companies with expertise in discovery of drugs targeting nuclear hormone receptors are preferred partners of Big Pharma and Biotech companies if they have identified novel scaffolds of RORgamma antagonists. More than ten such technology-pharma partnerships have been founded and already lead to first successes. Three RORgamma antagonists (inverse agonists) are already in clinical development and more to follow in 2016 and thereafter.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=556098
The report explains the scientific rationale for discovering antagonists of RORgamma for treatment of autoimmune and inflammatory diseases, but also of agonists of RORgamma for treatment of cancer. Clinical as well as non-clinical data for target validation of RORgamma are provided. Lead and up-side indications for development including the key product profile are discussed. Potential safety concers for novel RORgamma modulators were identified. Drug discovery approaches of technology and pharmaceutical companies are shown regarding strategies in partnering as well as in technologies applied for structure-based drug discovery. Based on the experience in the past, estimates of the required time from start of a discovery program of RORgamma modulators until entry into human studies are calculated. The competitive landscape of RORgamma modulator development and discovery projects is analyzed and the profiles of companies elaborated, separately for unpartnered technology or pharmaceutical companies and for partnerships between technology and pharmaceutical companies.
The report provides an understanding of:
The target RORgamma
Clinical and non-clinical target validation
Clinical lead and up-side indications
Drug discovery strategies and technologies
Commercial value of drug discovery collaborations
R&D timelines from start of screening to first-in-human studies
Competitive landscape of RORgamma antagonists
Agonists of RORgamma for cancer
Profiles of unpartnered technology companies and lead projects
R&D Partnerships and their discovery approaches and lead molecules
Unpartnered pharmaceutical companies and their programs
Browse Detail Report With TOC @ http://www.researchmoz.us/rorgamma-modulators-2016-a-comparative-analysis-of-the-landscape-of-rorgamma-antagonists-and-agonists-report.html
Table of Contents
1) Introduction
2) Executive Summary
3) Target Background
4) Target validation
Clinical Success of Anti-IL17 Antibodies
Non-Clinical Target Validation
Clinical Lead Indication for RORgamma Antagonists
Target-related Potential Safety Concerns
5) Drug Discover Approaches & Technologies
Drug Discovery Collaboration
Commercial Value of RORgamma Modulator Drug Discovery Collaborations
R&D Timelines for Discovery of RORgamma Antagonists in Partnership Programs
Strategies for the Discovery of Nuclear Receptor Ligands
6) Competitive Landscape of RORgamma Modulators
RORgamma Antagonists for Inflammatory and Autoimmune Diseases
Agonists of RORgamma for Cancer
7) Corporate Stakeholders
Unpartnered Technology Companies
Partnerships
Unpartnered Pharmaceutical Companies
8) References
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=556098
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Browse Our Latest Press Releases @ http://www.researchmoz.us/pressrelease
Researchmoz Global Pvt.Ltd
Researchmoz
+1-518-621-2074
sales@researchmoz.us
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
